Published in Cell on January 30, 2014
Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57
The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med (2015) 1.44
Macrophages are critical effectors of antibody therapies for cancer. MAbs (2015) 1.09
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
A hostel for the hostile: the bone marrow niche in hematologic neoplasms. Haematologica (2015) 0.99
Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer (2015) 0.95
Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol (2015) 0.89
Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol (2017) 0.86
Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance. Carcinogenesis (2014) 0.83
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol (2016) 0.83
The promise and challenge of ovarian cancer models. Transl Cancer Res (2015) 0.82
Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies? Protein Cell (2014) 0.82
Tumour immunology: turning macrophages on, off and on again. Nat Rev Immunol (2014) 0.81
XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene (2015) 0.81
A Systematic Approach to Identify Markers of Distinctly Activated Human Macrophages. Front Immunol (2015) 0.80
Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. Clin Exp Immunol (2015) 0.78
IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med (2016) 0.78
The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia. Leukemia (2016) 0.78
Modeling Natural Killer Cell Targeted Immunotherapies. Front Immunol (2017) 0.75
Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes. Genes Cancer (2016) 0.75
New developments in the treatment of multiple myeloma - clinical utility of daratumumab. Biologics (2017) 0.75
Resistance: turning macrophages on, off and on again. Nat Rev Cancer (2014) 0.75
Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J (2017) 0.75
Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy. Oncoimmunology (2015) 0.75
Cancer therapy: know your enemy? Mol Cell Pediatr (2014) 0.75
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy. Cancer Immunol Res (2015) 0.75
Modeling of Patient Derived Xenografts in Colorectal Cancer. Mol Cancer Ther (2017) 0.75
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer (2017) 0.75
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
Contributions of human tumor xenografts to anticancer drug development. Cancer Res (2006) 4.72
The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med (1995) 4.25
Prostaglandins as modulators of immunity. Trends Immunol (2002) 4.15
Immune therapy for cancer. Annu Rev Immunol (2009) 3.71
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
Double-hit B-cell lymphomas. Blood (2010) 3.19
Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest (2000) 3.03
Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell (2011) 2.64
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med (2008) 2.44
Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res (2010) 2.25
Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res (1993) 2.03
In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet (2009) 1.99
Macrophages as mediators of tumor immunosurveillance. Trends Immunol (2010) 1.80
Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. Nucleic Acids Res (2007) 1.68
Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem Pharmacol (2001) 1.56
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood (2008) 1.55
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood (2011) 1.34
Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. Cancer Cell (2011) 1.21
Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene (2012) 0.99
Risk/MRD adapted GMALL trials in adult ALL. Ann Hematol (2004) 0.90
Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin Oncol (2003) 0.82